Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to assess the proportion of participants in the
infliximab plus naproxen arm versus the placebo plus naproxen arm, in a population of
participants with moderate-to-severe active axial spondyloarthritis and disease duration of
≤3 years, who achieve the Assessment in Ankylosing Spondylitis (ASAS) partial remission
criteria.